Lawrence Dobroff Net Worth

The estimated Net Worth of Lawrence Dobroff is at least $1.34 Milione dollars as of 16 June 2005. Lawrence Dobroff owns over 14,819 units of Biospecifics Technologies stock worth over $1,311,926 and over the last 19 years Lawrence sold BSTC stock worth over $23,085.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Lawrence Dobroff BSTC stock SEC Form 4 insiders trading

Lawrence has made over 3 trades of the Biospecifics Technologies stock since 2005, according to the Form 4 filled with the SEC. Most recently Lawrence sold 10,000 units of BSTC stock worth $9,600 on 20 July 2006.

The largest trade Lawrence's ever made was selling 14,819 units of Biospecifics Technologies stock on 22 June 2005 worth over $13,485. On average, Lawrence trades about 13,213 units every 133 days since 2005. As of 16 June 2005 Lawrence still owns at least 14,819 units of Biospecifics Technologies stock.

You can see the complete history of Lawrence Dobroff stock trades at the bottom of the page.

What's Lawrence Dobroff's mailing address?

Lawrence's mailing address filed with the SEC is 15 SOUTHWICK COURT NORTH, , PLAINVIEW, NY, 11803.

Insiders trading at Biospecifics Technologies

Over the last 33 years, insiders at Biospecifics Technologies have traded over $67,860,045 worth of Biospecifics Technologies stock and bought 7,761,661 units worth $656,708,120 . The most active insiders traders include Capital Management, Llc Kol..., International Plc Endo e Max Link. On average, Biospecifics Technologies executives and independent directors trade stock every 73 days with the average trade being worth of $6,538,649. The most recent stock trade was executed by International Plc Endo on 2 December 2020, trading 7,344,955 units of BSTC stock currently worth $650,028,518.

What does Biospecifics Technologies do?

Complete history of Lawrence Dobroff stock trades at Biospecifics Technologies

Biospecifics Technologies executives and stock owners

Biospecifics Technologies executives and other stock owners filed with the SEC include:

• Jennifer Chao,
  Independent Chairman of the Board
• Michael Schamroth,
  Independent Director
• Paul Gitman,
  Independent Director
• Mark Wegman,
  Director
• Toby Wegman,
  Director
• Sarah McCabe,
  Stern Investor Relations
• Michael Sherman,
  Independent Director
• Corey Fishman,
  Independent Director
• Alex Monteith,
  Senior Vice President and Chief Business Officer
• Patrick Hutchison,
  Chief Financial Officer
• Joseph Truitt,
  Chief Executive Officer, Director
• Jeffrey Kenneth Vogel,
  
• Jyrki Mattila,
  Director
• Thomas Wegman,
  President
• Of Edwin H. Wegman Estate,
  10% owner
• Patrick M Caldwell,
  Principal Financial Officer
• Partners Lp Bio,
  10% owner
• Albert Horcher,
  
• Lawrence Dobroff,
  CFO
• Max Link,
  Director
• Henry Morgan,
  Director
• George M Gould,
  Director
• Matthew Geller,
  Director
• Capital Management, Llc Kol...,
  
• Capital Management, Llcra C...,
  
• Capital Management, Llcaldr...,
  
• Capital Management, Llc Kol...,
  
• Capital Management, Llcra C...,
  
• J Kevin Buchi,
  Chief Executive Officer
• International Plc Endo,
  10% owner